Wells Fargo & Company Igm Biosciences, Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 7,444 shares of IGMS stock, worth $10,272. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,444
Previous 4,987
49.27%
Holding current value
$10,272
Previous $82,000
45.12%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding IGMS
# of Institutions
86Shares Held
20.5MCall Options Held
68KPut Options Held
52.2K-
Baker Bros. Advisors LP New York, NY4.09MShares$5.65 Million0.72% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.01MShares$5.54 Million0.01% of portfolio
-
Siren, L.L.C. New York, NY3.33MShares$4.6 Million2.75% of portfolio
-
Redmile Group, LLC San Francisco, CA3.07MShares$4.24 Million3.32% of portfolio
-
Goldman Sachs Group Inc New York, NY978KShares$1.35 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $40M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...